Oral Switch in Bloodstream Infections in Immunocompromised Children
NCT07923266, Phase 4, Recruiting, Copenhagen University Hospital, Rigshospitalet
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Oral Switch in Bloodstream Infections in Immunocompromised Children | ClinicalTrials.gov |
| NCT number | NCT07923266 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Phase 4 | ClinicalTrials.gov |
| Enrollment | 114 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Copenhagen University Hospital, Rigshospitalet | ClinicalTrials.gov |
| Conditions | Bloodstream Infection, Bloodstream Infection Due to Central Venous Catheter, Immunocompromised Patients, Bacteremia Sepsis | ClinicalTrials.gov |
| Interventions | Oral antibiotic therapy, Standard IV antibiotic therapy | ClinicalTrials.gov |
| First posted | 2026-11-06 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Recurrence of blood stream infection | Within 6 weeks after randomization | Number of patients who experience growth of the same bacteria as in the index blood stream infection in a subsequent blood culture during the follow-up period. | ClinicalTrials.gov |
| Secondary | IV antibiotic treatment duration | Within 6 weeks after randomization | Duration of IV antibiotic treatment from randomization until completion of IV antibiotic treatment for the index bloodstream infection, measured in hours. | ClinicalTrials.gov |
| Other | Length of Hospital Stay | From randomization until discharge for the index bloodstream infection, assessed up to 42 days after randomization | Length of Hospital Stay for index infection | ClinicalTrials.gov |
| Other | Escalation of antibiotics | From randomization until completion of treatment for the index bloodstream infection, assessed up to 42 days after randomization | Proportion of participants with at least one escalation of antibiotic treatment for the index bloodstream infection, defined as a switch from oral to intravenous antibiotics or from intravenous antibiotics to a broader-spectrum intravenous regimen. | ClinicalTrials.gov |
| Other | Re-initiation of antibiotics | From randomization until completion of treatment for the index bloodstream infection, assessed up to 42 days after randomization | Re-initiation of antibiotics after completion of antibiotic treatment for the index infection (regardless of the indication) | ClinicalTrials.gov |
| Other | Treatment failure, other than blood stream infection | Within 6 weeks after randomization | Treatment failure, other than blood stream infection, defined as clinically and/or microbiologically confirmed disease progression or relapse, adjudicated by an independent, blinded adjudication committe | ClinicalTrials.gov |
| Other | Long term treatment failure | Within 3 months after randomization | Long term treatment failure, including blood stream infection, defined as clinically and/or microbiologically confirmed disease progression or relapse, adjudicated by an independent, blinded adjudication committee | ClinicalTrials.gov |
| Other | Number of Participants with Safety Outcomes | Within 6 weeks after randomization | Safety outcomes are admission to an intensive care unit and death | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)